Total Funding
31
1
Total FundingGrant raised
Growth Score
-3 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
371284
Alkahest develops therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline.
Tony Wyss-Coray: Co-Founder, Board Member & Chairman
About the Company
Alkahest develops therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline. It collaborates with Barcelona, Spain-based Grifols, a global healthcare company producer of plasma therapies. The company’s breakthrough research has demonstrated that factors in the blood plasma of young mice are able
to reverse brain deficits in normal aging and Alzheimer’s disease models in mice.
The company was founded in 2014 and is based in San Carlos, California.
